Stock Taper
SCREENER COMPARE ANY 2 STOCKS
ONC
BEONE MEDICINES AG
NASDAQ
$366.73
▼ DOWN 1.55% (-5.76)

KEY STATISTICS

Market Cap$39.19 B
52w High$385.22
52w Low$253.95
Dividend Yield—
Frequency—
P/E64.57
Volume295.94K
Shares Out.106.86M

COMPANY

LEADERSHIP

John V. Oyler
CHIEF EXECUTIVE
John V. Oyler

ABOUT

SECTOR
Healthcare
WENT PUBLIC
February 3, 2016
METHOD OF GOING PUBLIC
N/A
FULL TIME EMPLOYEES
12,000

PRICE TARGET

Target High$451.00
Target Low$367.00
Target Median$400.00
Target Consensus$400.67

UPCOMING EARNINGS

DateNov 5, 2026
DayThursday
Rev. Est.$1.75B
NOV
5
THU

PRICE

$366.73 ▼ DOWN 1.55% (−$5.76)
$366$368$370$3729:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM366.73

About BeOne Medicines AG

https://beonemedicines.com ↗

BeOne Medicines, a global oncology leader rebranded in 2024 and based in Basel, develops innovative cancer therapies like Tevimbra and Brukinsa, combining internal R&D and partnerships to target hematologic and solid tumors worldwide.

INDUSTRY

Biotechnology

A PRODUCT BEONE MEDICINES AG IS KNOWN FOR

Tevimbra (tislelizumab)
Tevimbra (tislelizumab)

An anti-PD-1 monoclonal antibody targeting solid tumors, recently approved in 2025 for advanced esophageal squamous cell carcinoma, is a key component of the company's immunotherapy portfolio to enhance immune detection and fight tumors.

COMPETITORS

COMPETITOR
AZN COMPARE
BMY COMPARE
MRK COMPARE
PFE COMPARE
REGN COMPARE

Revenue by Products

IconPRODUCTQ3-2025Q4-2025Q1-2026Q2-2026
Product$1.77B $1.9B ▲$1.89B ▼$2.21B ▲
Collaboration— $39M — —

Revenue by Geography

MapREGIONQ3-2025Q4-2025Q1-2026Q2-2026
UNITED STATES$754.86M $863.83M ▲$782.25M ▼$914.21M ▲
CHINA$439.88M $407.13M ▼$471.97M ▲$506.02M ▲
Europe$166.58M $173.85M ▲$194M ▲$208.75M ▲
All Other Countries Except China And United States Of America$50.97M — $65.21M ▲$76.09M ▲

ETFS HOLDING THIS STOCK

ETFS HOLDING
42
LISTED HERE
21
RANKED BY POSITION SIZE
IBB
2.06% · 594.1K
FBT
3.78% · 303.1K
CGGO
0.33% · 106.6K
BBH
3.08% · 39.8K
2820.HK
9.99% · 24.1K
CANC
3.24% · 18.7K
EMEQ
0.86% · 14.7K
DFAE
0.05% · 13.2K
AVEM
0.01% · 11.3K
ONEQ
0.03% · 8.2K
APIE
0.20% · 6.2K
XCHA.L
0.05% · 2.9K
NS
NSI
2.00% · 2.2K
IBBQ
0.78% · 2.1K
ETLI.DE
2.77% · 1.8K
SPWO
0.29% · 1.8K
BIB
0.43% · 1.2K
BOUT
1.96% · 826
ESIM
0.82% · 470
NTSE
0.18% · 273
HELX
0.28% · 241

INSTITUTIONAL OWNERSHIP

SHARES OWNED
34.17%
HOLDERS
368
TOP 12 OF 368 · RANKED BY POSITION SIZE
Baker Bros. Advisors LP
8.8M sh · $2.51B
Capital International Investors
5.1M sh · $1.55B
Primecap Management Co/Ca/
5.0M sh · $1.43B
Fmr LLC
4.0M sh · $1.21B
Oak Hill Advisors LP
2.8M sh · $39.12M
Capital World Investors
2.2M sh · $641.06M
Thomas J. Herzfeld Advisors, Inc.
2.1M sh · $29M
Citadel Advisors LLC
1.4M sh · $406.23M
Price T Rowe Associates Inc /Md/
1.4M sh · $417.03M
Gcm Grosvenor Holdings, LLC
1.4M sh · $19.31M
Rivernorth Capital Management, LLC
1.3M sh · $18.85M
Hhlr Advisors, Ltd.
1.0M sh · $307.16M

RATINGS SNAPSHOT

Overall rating: B

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity4
Return On Assets4
Debt To Equity3
Price To Earnings3
Price To Book1
Overall Score3

INSIDER TRADES

★
OFFICER: PRESIDENT AND COO
Wu Xiaobin
Sale · 280 shares
2026-08-25
★
OFFICER: SVP, GENERAL COUNSEL
Lee Chan Henry
Sale · 13.8K shares
2026-08-11
★
OFFICER: SVP, GENERAL COUNSEL
Lee Chan Henry
Sale · 2.7K shares
2026-08-11
★
OFFICER: SVP, GENERAL COUNSEL
Lee Chan Henry
Sale · 10.6K shares
2026-08-11

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 5
OVERWEIGHT 3
OUTPERFORM 2
MARKET OUTPERFORM 1
11 GRADES IN THE LAST 12 MONTHS
Barclays OVERWEIGHT Citizens MARKET OUTPERFORM Guggenheim BUY RBC Capital OUTPERFORM TD Cowen BUY Truist Securities BUY JP Morgan OVERWEIGHT Jefferies BUY

SECTORS PEERS

PEERPRICE
NTRA$326.26COMPARE
HUM$385.54COMPARE
A$153.85COMPARE
IQV$261.75COMPARE
ALC$72.01COMPARE
RMD$240.33COMPARE
GEHC$71.72COMPARE
MTD$1398.58COMPARE